Fracture during oral bisphosphonate therapy is associated with deteriorated bone material strength index

Fracture during oral bisphosphonate therapy is associated with deteriorated bone material strength index

BACKGROUND: Some patients experience fractures while receiving oral bisphosphonates (BPs) treatment. Clinical risk factors, advanced bone density loss, and microarchitecture deterioration have been associated with such fractures but bone tissue properties other than bone mineral density (BMD) have n...

Full description

Bibliographic Details
Main Authors:	Nogués, X, Prieto-Alhambra, D, Güerri-Fernández, R, Garcia-Giralt, N, Rodriguez-Morera, J, Cos, L, Mellibovsky, L, Pérez, A
Format:	Journal article
Language:	English
Published:	Elsevier 2017

Similar Items

HIV Infected Patients have Deteriorated Bone Material Properties at a Tissue Level Measured by "in vivo" Microindentation
by: Guerri Fernandez, R, et al.
Published: (2013)

HIV infection, bone metabolism, and fractures.
by: Güerri-Fernández, R, et al.
Published: (2014)

Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: Beneficial effect of bisphosphonates
by: Pineda-Moncusí, M, et al.
Published: (2019)

GGPS1 mutation and atypical femoral fractures with bisphosphonates.
by: Roca-Ayats, N, et al.
Published: (2017)

Bone Material Strength by Microindentation in Patients Initiating Glucocorticoids and Effect of Treatments
by: Torres-Del-Pliego, E, et al.
Published: (2013)

Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.
by: Prieto-Alhambra, D, et al.
Published: (2014)

PREDICTORS OF INADEQUATE RESPONSE TO ORAL BISPHOSPHONATE THERAPY: A POPULATION-BASED COHORT STUDY
by: Round, G, et al.
Published: (2012)

Genetic determinants of bone mineral density loss in Aromatase inhibitors treatment
by: Rodriguez-Sanz, M, et al.
Published: (2013)

Predictors of second fracture while on treatment with oral bisphosphonates: a multinational cohort study
by: Hawley, S, et al.
Published: (2014)

Oral bisphosphonate use reduces cardiovascular events in a cohort of Danish patients referred for bone mineral density
by: Rodriguez, AJ, et al.
Published: (2020)

Vitamin D repletion and aromatase inhibitor-related bone loss in women non treated with bisphosphonates
by: Prieto-Alhambra, D, et al.
Published: (2011)

Analyses of RANK and RANKL in the post-GWAS context: functional evidence of vitamin D stimulation through a RANKL distal region.
by: Yoskovitz, G, et al.
Published: (2013)

The association between calcium ± vitamin D supplementation and fracture risk among incident users of oral bisphosphonates: a population-based cohort study
by: Reyes, C, et al.
Published: (2015)

Functional effects of the p.Asp188Tyr mutation in the Geranylgeranyl Diphosphate Synthase (GGPS1) gene associated with bisphosphonate-related atypical femoral fractures
by: Roca-Ayats, N, et al.
Published: (2017)

Predicting imminent fractures in patients with a recent fracture or starting oral bisphosphonate therapy: development and international validation of prognostic models
by: Khalid, S, et al.
Published: (2021)

Oral bisphosphonates and chronic kidney disease: progression and safety
by: Prieto-Alhambra, D, et al.
Published: (2018)

A PREDICTIVE TOOL FOR ORAL BISPHOSPHONATE THERAPY DISCONTINUATION WITHIN INCIDENT USERS: A POPULATION-BASED COHORT STUDY
by: Round, G, et al.
Published: (2012)

Bone material strength index by microin-dentation correlates with chitotriosidase levels in patients with type 1 Gaucher disease
by: Diez-Perez, A, et al.
Published: (2017)

Brief report: HIV infection is associated with worse bone material properties, independently of bone mineral density
by: Güerri-Fernández, R, et al.
Published: (2016)

Bone density and bone material strength measured by microindentation ten years after kidney transplant
by: Vilaplana, L, et al.
Published: (2013)

Genetic study of atypical femoral fractures using exome sequencing in three affected sisters and three unrelated patients
by: Roca-Ayats, N, et al.
Published: (2018)

Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis
by: Robinson, DE, et al.
Published: (2021)

Bisphosphonates and bone quality.
by: Pazianas, M, et al.
Published: (2014)

OBESITY AND FRACTURES: A POPULATION-BASED STUDY USING THE SIDIAP DATABASE
by: Prieto-Alhambra, D, et al.
Published: (2011)

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.
by: van Staa, T, et al.
Published: (2007)

Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
by: Nogues, X, et al.
Published: (2010)

Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study
by: Robinson, DE, et al.
Published: (2021)

Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study
by: Robinson, DE, et al.
Published: (2021)

HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study.
by: Güerri-Fernandez, R, et al.
Published: (2013)

Long-term effect of aromatase inhibitors on fracture risk compared to tamoxifen: A “real world” cohort study of continued treatment up to ten years of follow-Up
by: Pineda-Moncusi, M, et al.
Published: (2018)

Oral bisphosphonate use and latent class trajectories of kidney function: A cohort study
by: Strauss, V, et al.
Published: (2018)

Patients With atypical femur fractures have the same mortality as the background population--drug-dhanneling bias, bisphosphonate effects, and public health implications
by: Abrahamsen, B, et al.
Published: (2016)

Atrial fibrillation and the use of oral bisphosphonates.
by: Pazianas, M, et al.
Published: (2011)

CHARACTERIZATION OF HUMAN RANKL PROXIMAL PROMOTER AND THE EFFECT OF HORMONE AND CYTOKINE TREATMENTS
by: Garcia-Giralt, N, et al.
Published: (2013)

Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
by: Garriga, C, et al.
Published: (2018)

Imminent fracture risk amongst new users of oral bisphosphonates in actual practice settings: A multi-national European cohort study from Denmark, Spain, and the UK
by: Khalid, S, et al.
Published: (2019)

CTX as an early prediction on bone loss in women on aromatase inhibitors: the B-ABLE cohort study
by: Torres-Del-Pliego, E, et al.
Published: (2013)

Negative control time window to identify residual confounding in comparative effectiveness study: An example of bisphosphonate use and risk of fracture
by: Robinson, D, et al.
Published: (2018)

Functional characterization of a GGPPS variant identified in atypical femoral fracture patients and delineation of the role of GGPPS in bone-relevant cell types
by: Roca-Ayats, N, et al.
Published: (2018)

The effect of oral bisphosphonates on acute kidney injury, gastrointestinal events and hypocalcaemia in patients with chronic kidney disease
by: Robinson, D, et al.
Published: (2018)